Giant cell tumour of bone

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 338-344

  Thomas, David M ^a,b   Skubitz, Keith M ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Giant cell tumour of bone; Osteoclast; RANKL

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; COLONY STIMULATING FACTOR 1; DENOSUMAB; IMATINIB; METHACRYLIC ACID METHYL ESTER; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PHENOL; SORAFENIB; SUNITINIB; ZINC CHLORIDE; ZOLEDRONIC ACID; MONOCLONAL ANTIBODY; TNFSF11 PROTEIN, HUMAN;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG TOLERABILITY; HUMAN; HYPOXIA; OSTEOCLASTOMA; PATHOGENESIS; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; TREATMENT RESPONSE; BONE TUMOR; DRUG ANTAGONISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; GIANT CELL TUMOR OF BONE; HUMANS; RANK LIGAND;

EID: 67650341248     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832c951d     Document Type: Review

References (60)

1. WHO. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
2. Anract P, De Pinieux G, Cottias P, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop 1998; 22:19-26.
3. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987; 69:106-114.
4. Unni KK. Dahlin's bone tumors: general aspects and data on 11,087 cases. New York: Lippincott-Raven; 1996.
5. Werner M. Giant cell tumour of bone: morphological, biological and histo- genetical aspects. Int Orthop 2006; 30:484-489.
6. Guo W, Xu W, Huvos AG, et al.comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) 1999; 112:1101 -1104.
7. Sung HW, Kuo DP, Shu WP, et al. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am 1982; 64:755-761.
8. Rendina D, Mossetti G, Soscia E, et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; (421):218-224.
9. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; (153):106-120.
10. Ng ES, Saw A, Sengupta S, et al. Giant cell tumour of bone with late presentation: review of treatment and outcome. J Orthop Surg (Hong Kong) 2002; 10:120-128.
11. Dominkus M, Ruggieri P, Bertoni F, et al. Histologically verified lung metas- tases in benign giant cell tumours: 14 cases from a single institution. Int Orthop 2006; 30:499-504.
12. Osaka S, Toriyama M, Taira K, et al. Analysis of giant cell tumor of bone with pulmonary metastases. Clin Orthop Relat Res 1997; (335):253-261.
13. Kapoor SK, Jain V, Agrawal M, et al. Primary malignant giant cell tumor of bone: a series of three rare cases. J Surg Orthop Adv 2007; 16:89-92.
14. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al. 18F-FDG kinetics and gene expression in giantcell tumors. J Nucl Med 2004; 45:1528-1535.
15. Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005; 167:117-128.
16. Skubitz KM, Cheng EY, Clohisy DR, et al. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144:193-200.
17. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response totherapyofsofttissueand bonesarcomas: a systematic reviewand meta-analysis. Cancer TreatRev2004; 30:83-101.
18. Tateishi U, Yamaguchi U, Seki K, et al. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and softtissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33:683-691.
19. Atkins GJ, Haynes DR, Graves SE, et al. Expression ofosteoclastdifferentia- tion signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15:640-649.
20. Murata A, Fujita T, Kawahara N, et al. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005; 10:581 -588.
21. Nishimura M, Yuasa K, Mori K, et al. Cytological properties of stromal cells derived from giantcell tumor ofbone (GCTSC) which can induce osteoclast formation ofhuman blood monocytes withoutcell tocell contact. JOrthop Res 2005; 23:979-987.
22. Walker DG. Congenital osteopetrosis in mice cured by parabiotic union with normal siblings. Endocrinology 1972; 91:916-920.
23. WalkerDG. Control ofboneresorption byhematopoietictissue. Theinduction and reversal of congenital osteopetrosis in mice through use of bone marrow and splenic transplants. J Exp Med 1975; 142:651 -663.
24. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under asuitable microenvironmentprepared bybone marrow-derived stromal cells. Proc Natl Acad Sci U S A 1990; 87:7260-7264.
25. Wiktor-Jedrzejczak WW, Ahmed A, Szczylik C, Skelly RR. Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J Exp Med 1982; 156: 1516-1527.
26. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988; 123:2600-2602.
27. SudaT, UdagawaN, NakamuraI, et al. Modulation ofosteoclastdifferentiation by local factors. Bone 1995; 17:87S-91S.
28. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305-311.
29. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424.
30. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 2000; 97:10905-10910.
31. SimonetWS, LaceyDL, Dunstan CR, et al. Osteoprotegerin: anovel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
32. Schwartz HS, Jenkins RB, Dahl R, Dewald GW. Cytogenetic analyses in giant-cell tumors of bone. Clin Orthop Relat Res 1989; 240:250-260.
33. Itonaga I, Schulze E, Burge PD, et al. Phenotypic characterization of mono- nuclear and multinucleated cells of giant cell reparative granuloma of small bones. J Pathol 2002; 198:30-36.
34. WestRB, Rubin BP, MillerMA, et al. Alandscape effectin tenosynovial giant- cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 2006; 103:690-695.
35. Arnett TR, Gibbons DC, Utting JC, et al. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol 2003; 196:2-8.
36. Knowles HJ, Athanasou NA. Hypoxia-inducible factor is expressed in giantcell tumour of bone and mediates paracrine effects of hypoxia on monocyteosteoclast differentiation via induction of VEGF. J Pathol 2008; 215:56-66.
37. Niida S, Kondo T, Hiratsuka S, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A 2005; 102:14016-14021.
38. Becker WT, Dohle J, Bernd L, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90:1060-1067.
39. Vultvon Steyern F, BauerHC, TrovikC, et al. Treatmentoflocal recurrencesof giantcell tumourin long bonesaftercurettageand cementing. AScandinavian Sarcoma Group study. J Bone Joint Surg Br 2006; 88:531-535.
40. Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002; (397):248- 258.
41. Zhen W, Yaotian H, Songjian L, et al. Giant-cell tumour of bone. The long-term results of treatment by curettage and bone graft. J Bone Joint Surg Br 2004; 86:212-216.
42. Durr HR, Maier M, Jansson V, et al. Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol 1999; 25:610-618.
43. Cheng EY, Zwolak P, Manivel C, et al. Zoledronic acid release from poly- methylmethacrylatecarrierand in vitroactivityagainstgiantcell tumorofbone. In: Proceedings of the Musculoskeletal Tumor Society Annual Meeting. Phoenix: Musculoskeletal Tumor Society; 2008. p. 67.
44. MalawerMM, BickelsJ, MellerI, et al. Cryosurgeryin thetreatmentofgiantcell tumor. A long-term followup study. Clin Orthop Relat Res 1999; (359):176- 188.
45. Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 2003; 57:158-165.
46. Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 1999; 81:1566-1573.
47. Feigenberg SJ, Marcus Jr RB, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 2003; (411):207-216.
48. Malone S, O'Sullivan B, Catton C, et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995; 33:689-694.
49. Bertoni F, Present D, Enneking WF. Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am 1985; 67:890-900.
50. Faisham WI, Zulmi W, Halim AS, et al. Aggressive giant cell tumour of bone. Singapore Med J 2006; 47:679-683.
51. Kaiser U, Neumann K, Havemann K. Generalised giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol 1993; 119:301 -303.
52. Maloney WJ, Vaughan LM, Jones HH, et al. Benign metastasizing giant-cell tumor of bone. Report of three cases and review of the literature. Clin Orthop Relat Res 1989; (243):208-215.
53. Kaban LB,Troulis MJ, Wilkinson MS, et al. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg 2007; 65:2018-2024; discussion 2024.
54. Cheng YY, Huang L, Lee KM, et al. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004; 75:71 -77.
55. Chang SS, Suratwala SJ, Jung KM, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 2004; (426):103-109.
56. Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai 2008; 91:1609-1612.
57. Fujimoto N, Nakagawa K, Seichi A, et al. A new bisphosphonate treatment option for giant cell tumors. Oncol Rep 2001; 8:643-647.
58. Tse LF, Wong KC, KumtaSM, et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008; 42:68-73.
59. Thomas D, Chawla SP, Skubitz K, et al. Denosumab treatment of giant cell tumor of bone: interim analysis of an open-label phase II study [meeting abstracts]. J Clin Oncol 2008; 26:10500. The preliminary data from this study indicated that targeting of RANKL is a novel, clinically effective therapeutic strategy in advanced GCT.
60. Blay JY, El Sayadi H, Thiesse P, et al.complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19:821 -822.